Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NGNEthis companyNeurogene Inc.	$26.18	-4.86×	1.65×	0×	-3.92×	-83.6%	0.0%	0.0%	0.0%	-34.1%	-37.5%	-18.0%	0.04×	1.08×	-20,641.6×	16.56×	0.0%	1	6.39	2	C
ALECAlector, Inc.	$2.45	-1.12×	5.24×	7.63×	-0.99×	-108.0%	54.1%	-692.8%	-679.2%	-466.3%	-62.5%	-114.6%	1.18×	0.22×	0×	3.83×	0.0%	2	-7.33	2	C
DSGNDesign Therapeutics, Inc.	$10.55	-7.69×	2.53×	0×	-7.55×	-97.5%	0.0%	0.0%	0.0%	-32.8%	-37.1%	-10.1%	0.01×	0.22×	0×	17.14×	0.0%	1	26.54	2	C
FDMT4D Molecular Therapeutics, Inc.	$12.59	-3.1×	0.86×	5.1×	-2.99×	-184.8%	91.1%	-187.2%	-164.4%	-27.7%	-30.2%	-25.1%	0.04×	0.29×	0×	9.39×	0.0%	3	1.71	2	C
LXEOLexeo Therapeutics, Inc. Common Stock	$3.09	-5.34×	2.16×	0×	-4.89×	-69.1%	0.0%	0.0%	0.0%	-40.5%	-42.9%	-18.6%	0.03×	0.56×	-530.37×	11.21×	0.0%	1	5.08	2	B-
MGTXMeiraGTx Holdings plc	$9.40	-5.6×	-110.38×	7.86×	-7.4×	-554.4%	94.0%	-130.2%	-140.3%	1971.4%	-70.9%	-7.8%	-15.31×	-0.25×	-8.69×	0.75×	0.0%	6	4.07	3	B
Peer median	—	-5.34×	2.16×	5.1×	-4.89×	-108.0%	54.1%	-130.2%	-140.3%	-32.8%	-42.9%	-18.6%	0.03×	0.22×	0×	9.39×	0.0%	2	4.07	2	—